Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Now, in a new study published on the preprint server, bioRxiv researchers in the U.S. investigated a soluble version of ACE2 for SARS-CoV-2 viral neutralization activity.
Pulmonary hypertension is a serious problem associated with a wide variety of lung diseases, which can lead to right ventricular dysfunction and death.
A Turkish family from a village near the Black Sea first caught the attention of medical researchers in the early 1970s.
The Deutsche Forschungsgemeinschaft is establishing ten new Collaborative Research Centres to further support top-level research in German universities.
A new research paper published in the journal JAMA Network Open in May 2020 reports a high incidence of deep vein clots in patients with severe COVID-19 at a single French medical center. This could indicate the need for systematic anticoagulant therapy in these patients as a preventive measure.
UCI Health will initiate a clinical study of a drug to treat critically ill COVID-19 patients who face a high mortality rate because of acute inflammation that fills their lungs with fluid, a grave condition that even mechanical ventilation cannot improve.
A study conducted by a team of researchers at LSU Health New Orleans has shown for the first time that chronic exposure to inhaled nicotine alone increases blood pressure (hypertension), in both the body's general circulation and in the lungs that can lead to pulmonary hypertension.
The Critical Path Institute (C-Path) today announced that its Type 1 Diabetes (T1D) Consortium has received a letter of support from the European Medicines Agency (EMA) to facilitate the development and validation of the proposed regulatory qualification of pancreatic islet autoantibodies commonly used in clinical practice to diagnose T1D: insulin autoantibodies, glutamic acid decarboxylase 65, and insulinoma antigen-2 autoantibodies as enrichment biomarkers for T1D clinical trials.
COVID-19 disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a highly infectious disease. As of today, over 170,000 people worldwide have succumbed to the infection. Reports have shown that some comorbidities and illnesses raise the risk of getting infected and also influence the severity of the disease. Having a compromised immune system can also drastically raise the risk of getting COVID-19.
New guidance is available for physicians who must go through a number of steps to provide a probable diagnosis of sarcoidosis - an inflammatory disease that affects the lungs, lymph glands, and other organs.
Q: Starting from the patient admission to the hospital, what is your rule for ventilation? Do you start from HFNC, CPAP, NIV or go directly to intubation and invasive ventilation when the conventional oxygen therapy fails?
Factoring in the total number of days that extremely preterm infants require supplemental oxygen and tracking this metric for weeks longer than usual improves clinicians' ability to predict respiratory outcomes according to bronchopulmonary dysplasia severity, a research team led by Children's National Hospital writes in Scientific Reports.
A new study published in the journal Nature Communications in February 2020 shows that secretions from stem cells in the lung can be utilized to nebulize injured lungs due to several types of lung fibrosis in rats and mice. This could well result in the development of less invasive and more effective therapies for lung fibrosis.
A research team led by Dr. Yunching Chen and Tsai-Te Lu of National Tsing Hua University have recently developed a new treatment for cancer, in which blood vessels within malignant tumors are normalized by injecting a specially developed nanodelivery system for nitric oxide (NanoNO), which also facilitates the delivery of cancer drugs and immunocytes into the tumor.
A team of researchers has found that the microflora of bacteria within the gut of humans could be a contributor to the development of pulmonary arterial hypertension (PAH). The study titled, "Altered Gut Microbiome Profile in Patients With Pulmonary Arterial Hypertension," in the latest issue of the American Heart Association's journal Hypertension.
Researchers have identified a distinct collection of bacteria found in the gut that may contribute to and predict the development of pulmonary arterial hypertension, according to new research published today in the American Heart Association's journal Hypertension.
The invention of interactive map applications has revolutionized wayfinding, providing an unprecedented level of information far beyond what printed road maps can offer.
Pulmonary hypertension is a type of high blood pressure that affects the lungs of both animals and people. When tiny vessels in the lungs become narrowed or blocked, it becomes harder for blood to flow through and can cause the heart to weaken or fail.
International physiologists and researchers studying the kidney, high blood pressure and related medical conditions will convene next week at the American Physiological Society (APS) Aldosterone and ENaC in Health and Disease: The Kidney and Beyond Conference in Estes Park, Colo.
The European Society of Cardiology Guidelines on acute pulmonary embolism are published online today in European Heart Journal, and on the ESC website. They were developed in collaboration with the European Respiratory Society.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.